Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Department of Stomatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China.
Clin Epigenetics. 2021 Jan 29;13(1):22. doi: 10.1186/s13148-020-00989-0.
The recent discovery of cancer/tissue specificity of miRNA has indicated its great potential as a therapeutic target. In Epstein-Barr virus-associated gastric cancer (EBVaGC), host genes are affected by extensive DNA methylation, including miRNAs. However, the role of methylated miRNA in the development of EBVaGC and immune cell infiltration has largely remained elusive.
After crossmatching the DNA methylation and expression profile of miRNA and mRNA in the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas Research Network (TCGA), we discovered that miR-129-2-3p was significantly suppressed due to hypermethylation on its enhancer in EBVaGC. The differentially expressed genes (DEGs) added up to 30, among which AKAP12 and LARP6 were predicted to be the target genes of miR-129-2-3p and negatively correlated with patients' survival. Accordingly, miR-129-2-3p was significantly down-regulated in tumor samples in 26 (65%) out of 40 cases in our cohort (P < 0.0001). The proliferation, migration and invasion functions of GC cells were significantly promoted when transfected with miR-129-2-3p inhibitor and suppressed when transfected with mimics or treated with 5-aza-2'-deoxycytidine. Moreover, a comprehensive regulation network was established by combining the putative transcription factors, miRNA-mRNA and protein-protein interaction (PPI) analysis. Pathway enrichment analysis showed that cytokine activity, especially CCL20, was the most prominent biological process in EBVaGC development. Immune cell infiltration analysis demonstrated CD4 T cell, macrophage and dendritic cell infiltrates were significantly enriched for the prognostic-indicated hub genes.
This study has provided a comprehensive analysis of differentially expressed miRNAs and mRNAs associated with genome-wide DNA methylation by integrating multi-source data including transcriptome, methylome and clinical data from GEO and TCGA, QPCR of tumor samples and cell function assays. It also gives a hint on the relationships between methylated miRNA, DEGs and the immune infiltration. Further experimental and clinical investigations are warranted to explore the underlying mechanism and validate our findings.
最近发现 miRNA 具有癌症/组织特异性,这表明它作为治疗靶点具有巨大潜力。在 Epstein-Barr 病毒相关胃癌(EBVaGC)中,宿主基因受到广泛的 DNA 甲基化的影响,包括 miRNA。然而,甲基化 miRNA 在 EBVaGC 发展和免疫细胞浸润中的作用在很大程度上仍然难以捉摸。
在交叉匹配 miRNA 的 DNA 甲基化和表达谱以及基因表达综合数据库(GEO)和癌症基因组图谱研究网络(TCGA)中的 mRNA 后,我们发现 miR-129-2-3p 由于其增强子的超甲基化而在 EBVaGC 中受到显著抑制。差异表达基因(DEGs)加起来有 30 个,其中 AKAP12 和 LARP6 被预测为 miR-129-2-3p 的靶基因,并与患者的生存呈负相关。相应地,在我们的队列中,40 例肿瘤样本中有 26 例(65%)miR-129-2-3p 明显下调(P < 0.0001)。当用 miR-129-2-3p 抑制剂转染时,GC 细胞的增殖、迁移和侵袭功能显著增强,而用 mimics 转染或用 5-氮杂-2'-脱氧胞苷处理时则受到抑制。此外,通过结合假定的转录因子、miRNA-mRNA 和蛋白质-蛋白质相互作用(PPI)分析,建立了一个全面的调控网络。通路富集分析表明,细胞因子活性,特别是 CCL20,是 EBVaGC 发展中最显著的生物学过程。免疫细胞浸润分析表明,预后指示枢纽基因的 CD4 T 细胞、巨噬细胞和树突状细胞浸润显著富集。
本研究通过整合包括 GEO 和 TCGA 转录组、甲基组和临床数据、肿瘤样本 qPCR 和细胞功能测定在内的多源数据,对与全基因组 DNA 甲基化相关的差异表达 miRNA 和 mRNAs 进行了全面分析。它还提示了甲基化 miRNA、DEGs 和免疫浸润之间的关系。需要进一步的实验和临床研究来探索潜在的机制并验证我们的发现。